Anc80 Resources

Anc80: a novel AAV capsid

Odylia has exclusive rights to the Anc80 AAV vector for use in developing gene therapies to treat rare and ultra-rare retinal diseases. Anc80 is an ancestral adeno-associated virus, which was discovered in 2015 in the lab of Luk H. Vandenberghe, at Massachusetts Eye and Ear. Dr. Vandenberghe’s laboratory discovered Anc80 through their efforts to identify safer, more effective viral vector-based delivery systems. Anc80 is predicted to be the ancestor of the broadly utilized AAV1, AAV2, AAV8, and AAV9, and can effectively transduce the retina, central nervous system, muscle, liver, and cells of the inner ear to name a few.

Learn about the impact Odylia is making

Questions? We’re here to help!